Yifeng Pharmacy Chain Future Growth

Future criteria checks 2/6

Yifeng Pharmacy Chain is forecast to grow earnings and revenue by 18.5% and 16.4% per annum respectively. EPS is expected to grow by 17.2% per annum. Return on equity is forecast to be 17.8% in 3 years.

Key information

18.5%

Earnings growth rate

17.2%

EPS growth rate

Consumer Retailing earnings growth	37.7%
Revenue growth rate	16.4%
Future return on equity	17.8%
Analyst coverage	Good
Last updated	17 Oct 2024

Recent future growth updates

Recent updates

The Market Lifts Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Shares 28% But It Can Do More

Sep 27

Investors Met With Slowing Returns on Capital At Yifeng Pharmacy Chain (SHSE:603939)

Jul 29

Slammed 27% Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Screens Well Here But There Might Be A Catch

Jun 20

Yifeng Pharmacy Chain (SHSE:603939) Seems To Use Debt Rather Sparingly

May 24

Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors

May 06

Is Now The Time To Put Yifeng Pharmacy Chain (SHSE:603939) On Your Watchlist?

Apr 13

Market Participants Recognise Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Earnings

Mar 28

Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Intrinsic Value Is Potentially 100% Above Its Share Price

Mar 13

Earnings and Revenue Growth Forecasts

SHSE:603939 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	36,311	2,450	3,258	4,497	16
12/31/2025	30,721	2,017	2,736	3,876	18
12/31/2024	24,926	1,587	2,139	3,007	11
6/30/2024	23,644	1,505	4,261	5,038	N/A
3/31/2024	23,293	1,482	3,173	3,985	N/A
12/31/2023	22,588	1,412	3,884	4,624	N/A
9/30/2023	22,427	1,437	3,989	4,494	N/A
6/30/2023	21,843	1,391	3,690	4,235	N/A
3/31/2023	21,004	1,330	4,037	4,561	N/A
12/31/2022	19,886	1,262	3,333	3,920	N/A
9/30/2022	17,736	1,016	2,090	2,792	N/A
6/30/2022	16,730	960	1,572	2,265	N/A
3/31/2022	15,845	919	1,400	2,203	N/A
12/31/2021	15,326	888	1,322	2,150	N/A
9/30/2021	14,646	867	1,670	2,381	N/A
6/30/2021	14,198	847	1,710	2,434	N/A
3/31/2021	13,726	798	1,812	2,486	N/A
12/31/2020	13,145	744	1,747	2,330	N/A
9/30/2020	12,324	698	1,490	1,994	N/A
6/30/2020	11,521	637	914	1,404	N/A
3/31/2020	10,855	583	743	1,203	N/A
12/31/2019	10,276	544	504	963	N/A
9/30/2019	9,636	526	399	774	N/A
6/30/2019	8,968	499	435	768	N/A
3/31/2019	7,900	463	344	604	N/A
12/31/2018	6,913	416	267	511	N/A
9/30/2018	6,054	402	172	394	N/A
6/30/2018	5,562	384	146	359	N/A
3/31/2018	5,211	345	N/A	345	N/A
12/31/2017	4,807	314	N/A	317	N/A
9/30/2017	4,480	285	N/A	205	N/A
6/30/2017	4,210	267	N/A	193	N/A
3/31/2017	3,978	241	N/A	161	N/A
12/31/2016	3,734	224	N/A	140	N/A
9/30/2016	3,540	210	N/A	207	N/A
6/30/2016	3,305	200	N/A	195	N/A
3/31/2016	3,040	187	N/A	160	N/A
12/31/2015	2,846	176	N/A	182	N/A
9/30/2015	2,615	169	N/A	229	N/A
6/30/2015	2,492	161	N/A	192	N/A
3/31/2015	2,373	150	N/A	235	N/A
12/31/2014	2,230	141	N/A	212	N/A
12/31/2013	1,804	99	N/A	157	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603939's forecast earnings growth (18.5% per year) is above the savings rate (2.9%).

Earnings vs Market: 603939's earnings (18.5% per year) are forecast to grow slower than the CN market (23.7% per year).

High Growth Earnings: 603939's earnings are forecast to grow, but not significantly.

Revenue vs Market: 603939's revenue (16.4% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 603939's revenue (16.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603939's Return on Equity is forecast to be low in 3 years time (17.8%).

Yifeng Pharmacy Chain Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 8.0% to CN¥39.55

Price target decreased by 15% to CN¥45.15

Price target decreased to CN¥64.76

Price target decreased to CN¥69.45

Price target decreased to CN¥68.15

Price target raised to CN¥104

Recent updates

Investor sentiment deteriorates as stock falls 18%

Yifeng Pharmacy Chain Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

The Market Lifts Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Shares 28% But It Can Do More

Investor sentiment improves as stock rises 24%

Price target decreased by 8.0% to CN¥39.55

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Investors Met With Slowing Returns on Capital At Yifeng Pharmacy Chain (SHSE:603939)

Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Slammed 27% Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Screens Well Here But There Might Be A Catch

Price target decreased by 15% to CN¥45.15

Investor sentiment deteriorates as stock falls 19%

Yifeng Pharmacy Chain (SHSE:603939) Seems To Use Debt Rather Sparingly

Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors

Full year 2023 earnings released: EPS: CN¥1.40 (vs CN¥1.26 in FY 2022)

Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 20, 2024

Is Now The Time To Put Yifeng Pharmacy Chain (SHSE:603939) On Your Watchlist?

Yifeng Pharmacy Chain Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Market Participants Recognise Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Earnings

Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Intrinsic Value Is Potentially 100% Above Its Share Price

Yifeng Pharmacy Chain Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment deteriorates as stock falls 33%

Now 20% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) completed the acquisition of a 51% stake in Hunan Jiuzhitang Pharmaceutical Co., Ltd. from Jiuzhitang Co., Ltd. (SZSE:000989).

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥64.76

Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) agreed to acquire 5% stake in Jiuzhitang Co., Ltd. (SZSE:000989) from Li Zhenguo for CNY 430 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Price target decreased to CN¥69.45

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.25 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.32 in 2Q 2020)

Investor sentiment improved over the past week

Price target decreased to CN¥68.15

First quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.35 in 1Q 2020)

New 90-day low: CN¥88.10

Investor sentiment improved over the past week

New 90-day low: CN¥88.50

Price target raised to CN¥104

New 90-day high: CN¥107

Third quarter earnings released

Yifeng Pharmacy Chain Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

New 90-day high - CN¥97.54

Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies